Drug
Serplulimab clinical trials
Also written HLX10.
- studies test it
- 97
- open now
- 66
- in phase 3
- 15
- first study started
- 2018
Keep track of what changes. Save the serplulimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
97 studies that test it; most in 2023 (26)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 13 |
| 2023 | 26 |
| 2024 | 13 |
| 2025 | 10 |
| 2026 | 23 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 76
- Phase 3
- 15
- Phase 4
- 1
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 71
Shanghai Henlius Biotech (24) · Fudan University (7) · Tianjin Medical University Cancer Institute and Hospital (4) · Fujian Cancer Hospital (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Sun Yat-sen University (3) · RenJi Hospital (3) · Henan Cancer Hospital (3)
Often tested with
Tested in the same studies.
Bevacizumab (9) · Paclitaxel (8) · HLX07 (6) · Cisplatin (5) · Carboplatin (5) · Albumin-Bound Paclitaxel (4) · Etoposide (4) · HLX04 (4)
Studies
Open first, then newest update. How each study uses serplulimab is read from its arms, and is right about nine times in ten.
Testing it · 97
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingPhase 2Fujian Medical University Union HospitalNCT06601309Written as Serplulimab
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT06860529Written as Serplulimab
- HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric CancerRecruitingPhase 2Shanghai Changzheng HospitalNCT07621484Written as Serplulimab
- A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal CancerNot yet recruitingNot applicableTang-Du HospitalNCT07854964Written as Serplulimab
- A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung CancerRecruitingPhase 2People's Hospital of QuzhouNCT07647094Written as Serplulimab, Nab-Paclitaxel, Carboplatin
- Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Xijing HospitalNCT07819604Written as Serplulimab
- 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal CancerNot yet recruitingPhase 2Zhejiang UniversityNCT07779694Written as Serplulimab + chemotherapy
- JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment FailureNot yet recruitingPhase 1/2West China HospitalNCT07175389Written as Serplulimab
- Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction AdenocarcinomaRecruitingPhase 2National Cancer Center, JapanNCT07699939Written as serplulimab
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingPhase 2Beijing Tiantan HospitalNCT07713745Written as Serplulimab
- Luvometinib in Combination With Serplulimab for NF2-Related TumorsNot yet recruitingPhase 1/2Beijing Tiantan HospitalNCT07708285Written as Serplulimab
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingPhase 1/2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT05747729Written as Surufatinib and Serplulimab
- Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07691632Written as Serplulimab + Decitabine + CAPOX (Oxaliplatin + Capecitabine)
- Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCRecruitingPhase 2Guangzhou Institute of Respiratory DiseaseNCT06497530Written as Serplulimab
- A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07622550Written as Serplulimab+Fruquintinib+XELOX
- A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant ChemotherapyRecruitingPhase 2Fudan UniversityNCT07604909Written as Serplulimab
- Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%RecruitingPhase 2Tang-Du HospitalNCT07596121Written as Serplulimab
- A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal CancerRecruitingPhase 3Tao ZhangNCT07113275Written as HLX10
- Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)RecruitingPhase 2RenJi HospitalNCT07283692Written as Serplulimab
- A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal CancerNot yet recruitingPhase 2Chongqing University Cancer HospitalNCT07543848Written as Serplulimab
See all 97 studies that test serplulimab →
Given in every arm · 31 — serplulimab is usual care beside what is tested
- Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSSNot yet recruitingPhase 3Fudan UniversityNCT07877597Written as Serplulimab
- Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort StudyNot yet recruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07872696Written as Serplulimab
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsEnrolling by invitationPhase 1Shanghai Henlius BiotechNCT06115642Written as HLX10
- Efficacy and Safety of Intraoperative Radiotherapy Combined With Serplulimab Plus Chemotherapy Versus Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07870798Written as Serplulimab
- Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaRecruitingPhase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07177443Written as Serplulimab
- A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07739758Written as Serplulimab
- Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 2Shanghai General Hospital, ChinaNCT07733050Written as Serplulimab and Bevacizumab injection
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNot applicableTang-Du HospitalNCT06128252Written as Serplulimab
- A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCRecruitingPhase 2Shanghai Henlius BiotechNCT07269782Written as Serplulimab
- Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled StudyRecruitingPhase 2Sun Yat-sen UniversityNCT07583511Written as serplulimab
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07231445Written as Serplulimab
- Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07507916Written as HLX10
- Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Zekuan XuNCT06461910Written as Serplulimab
- Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)Not yet recruitingPhase 2Xinhua Hospital, Shanghai Jiao Tong University School of MedicineNCT07381400Written as Serplulimab
- Serplulimab for Locally Advanced Cervical CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07340489Written as Serplulimab
- A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsRecruitingPhase 1/2Shanghai Henlius BiotechNCT06848699Written as Serplulimab
- Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07172412Written as Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab
- Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)RecruitingPhase 2Fudan UniversityNCT07150949Written as Serplulimab
- Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)Not yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07134101Written as Serplulimab
- A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid TumorsRecruitingPhase 1Guangzhou FineImmune Biotechnology Co., LTD.NCT06716619Written as Serplulimab Injection
Showing 20 of 31.
Codes
What other systems call serplulimab · ClinicalTrials.gg INT002208
- MeSH (NLM) C000732065serplulimabOne source NLM
- UNII (FDA) S3GQZ2K36VSERPLULIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q130351954serplulimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C156738SerplulimabOne source FDA
- DrugBank DB17451One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732065 | serplulimab | One source NLM |
| UNII (FDA) | S3GQZ2K36V | SERPLULIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130351954 | serplulimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C156738 | Serplulimab | One source FDA |
| DrugBank | DB17451 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.